Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma
In Partnership With:
In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.
Welcome to a very special edition of OncLive On Air! I’m your host today, Gina Columbus.
OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
But today, we had the pleasure of sitting down with Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center, where is also codirector of the Melanoma Research Program. Dr. Weber has been instrumental in key immunotherapeutic developments in oncology with a special focus in melanoma. To start, he’s led several studies of targeted therapies with dabrafenib and trametinib in the disease, as well as combinations with nivolumab and ipilimumab. He’s also aimed to advance a deeper understanding of immunotherapy-related adverse events and how to best manage them, as well as explore novel immunotherapy concepts.
For these reasons and many others, Weber was recognized as the 2016 OncLive Giant of Cancer Care® for Melanoma.
In our exclusive interview, Dr. Weber shared with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.
